ITCI Intra-Cellular Therapies: Price-to-Projected Revenue Ratio
The forward P/S ratio illustrates the valuation dynamics of Intra-Cellular Therapies (ITCI). Growth is driven by the success of CAPLYTA, a unique schizophrenia treatment devoid of tremor-related side effects. The 20.60 metric confirms current levels as the company expands the drug's application for depression. Robust cash flow and strong market momentum ensure sustainable margins and a confident growth trajectory.
intracellulartherapies.com (ITCI) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Equity Intra-Cellular Therapies|ITCI - Long-Term Debt to Equity|Short-Term Debt to Capital Intra-Cellular Therapies, Inc.|ITCI - Company Aggregate Debts|Debt to Book Capitalization Ratio Intra-Cellular Therapies, Inc.|ITCI - Company Long-Term Loans and Borrowings|Company Current Liabilities Intra-Cellular Therapies|Quick Liquidity Indicator intracellulartherapies.com
- business earnings and investment ratios data:
ITCI - Profit After Payment of Taxes|Projected Future Earnings Intra-Cellular Therapies|ITCI - Company Value to Net Income|Forward P/E Multiple Intra-Cellular Therapies, Inc.|ITCI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intra-Cellular Therapies, Inc.|ITCI - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Intra-Cellular Therapies|ITCI - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months intracellulartherapies.com|ITCI - Earnings per share trend in current year|Earnings growth forecast for next year Intra-Cellular Therapies
- sales revenue and business income indicators:
Fundamental company analysis:ITCI (Intra-Cellular)
The efficiency of Caplyta commercialization through clinic partnerships directly impacts the projected market cap-to-revenue ratio for Intra-Cellular Therapies (ITCI). This indicator compares the current market value of Intra-Cellular Therapies (ITCI) with projected 10-K/10-Q financial data, allowing investors to perform a real-time assessment of valuation fairness relative to expected sales and promptly identify risks of overpayment or business undervaluation.
Key competitors
Forward P/S Multiple BIIB (Biogen)|Neurocrine (NBIX) - Market Cap to Future Revenue Ratio|RGC - Price-to-Projected Revenue Ratio|AXSM: Price-to-Projected Revenue Ratio|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|XENE (xenon-pharma.com) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple VKTX|Forward P/S Multiple Supernus Pharmaceuticals, Inc.|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|Price-to-Projected Revenue Ratio DNLI (Denali Corp)|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward P/S Multiple biohavenpharma.com BHVN|AMLX - Price-to-Projected Revenue Ratio|Forward Price to Sales TRVI (Trevi Therapeutics Inc)|PRAX (Praxis Medicines) - Forward Price-to-Revenue Multiple|Anavex Life Sciences Corp - Forward Price to Sales|Forward Price-to-Revenue Multiple CBLL|PRTA (Prothena Corporation) - Price to Expected Revenue Ratio|Forward P/S Multiple ALEC|ANNX (Annexon Biosciences) - Forward Price to Sales|Forward P/S Multiple OMER (Omeros)|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|ACIU - Price-to-Projected Revenue Ratio|Forward Price to Sales VYGR (voyagertherapeutics.com)|NMRA: Forward P/S Multiple|Scilex Holding (SCLX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Alpha Cognition Corp - Future Price to Revenue|Forward P/S Multiple CGTX|Market Cap to Expected Sales Ratio inhibikase.com|Forward P/S Multiple SAVA (Cassava Sciences)|Assertio Holdings (ASRT) - Market Cap to Future Revenue Ratio|COYA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Vistagen Therapeutics VTGN|OVID: Forward P/S Multiple|ABOS - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CRVO|ATHE (Alterity Therapeutics Ltd) - Price to Expected Revenue Ratio|Forward P/S Multiple CLNN|Forward Price-to-Revenue Multiple pepgen.com PEPG|Forward P/S Multiple JUNS (Jupiter Neurosciences Inc)|Market Cap to Expected Sales Ratio relmada.com (RLMD)|ANVS - Price-to-Projected Revenue Ratio|GRCE (Grace Therapeutics, Inc.) - Market Cap to Projected Revenue|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences (KLTO)|Forward Price-to-Revenue Multiple NRSN|Forward P/S Multiple revivapharma.com|Price-to-Projected Revenue Ratio MetaVia Inc (MTVA)|NRXS (NeurAxis Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio Helius Medical Technologies HSDT|Passage Bio Inc. (PASG) - Market Cap to Future Revenue Ratio|Neuphoria - Forward P/S Multiple|Market Cap to Expected Sales Ratio minervaneurosciences.com NERV|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ADXN|Forward Price-to-Revenue Multiple ALZN|CYCN (Cyclerion) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Protagenic Therapeutics (PTIX)|KTTA (pasitheaclinics.com) - Forward Price to Sales|Forward P/S Multiple CRGT (Cortigent)|Forward P/S Multiple Avenue Therapeutics Inc. ATXI|BCLI: Forward Price-to-Revenue Multiple|Projected Price to Revenue Cara Therapeutics Inc (CARA)|CHRO: Forward P/S Multiple|Forward Price-to-Revenue Multiple Eliem Therapeutics Inc.|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Marinus Pharmaceuticals Inc MRNS|Price-to-Projected Revenue Ratio NKGen (NKGN)|Price-to-Projected Revenue Ratio NRBO (NeuroBo Pharma)|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|synaptogen.com - Price-to-Projected Revenue Ratio|TRVN: Forward Price-to-Revenue Multiple|VIGL - Forward P/S Multiple|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|CERE (Cerevel Corp) - Price-to-Projected Revenue Ratio
